

(19) 世界知的所有権機関
国際事務局



(43) 国際公開日
2004 年 7 月 22 日 (22.07.2004)

PCT

(10) 国際公開番号
WO 2004/060400 A1

(51) 国際特許分類⁷: A61K 45/00, 31/517, 31/519, 31/4709, 31/47, 31/4741, 31/496, A61P 25/18, 25/28, 43/00

(21) 国際出願番号: PCT/JP2004/000002

(22) 国際出願日: 2004 年 1 月 5 日 (05.01.2004)

(25) 国際出願の言語: 日本語

(26) 国際公開の言語: 日本語

(30) 優先権データ:
特願2003-034396 2003 年 1 月 6 日 (06.01.2003) JP

(71) 出願人 (米国を除く全ての指定国について): 三菱ウェルファーマ株式会社 (MITSUBISHI PHARMA CORPORATION) [JP/JP]; 〒5410046 大阪府大阪市中央区平野町二丁目 6 番 9 号 Osaka (JP).

(72) 発明者; および

(75) 発明者/出願人 (米国についてのみ): 那波 宏之 (NAWA, Hiroyuki) [JP/JP]; 〒9518104 新潟県新潟市西大畑町 5 2 1 4-3-2 0 1 Niigata (JP). 水野 誠 (MIZUNO, Makoto) [JP/JP]; 〒9518116 新潟県新潟市東中通 1 番町 8 6-1 1 3-3 1 0 Niigata (JP).

(74) 代理人: 高柳 昌生 (TAKAYANAGI, Masau); 〒1038405 東京都中央区日本橋本町二丁目 2 番 6 号三菱ウェルファーマ株式会社 知的財産部 Tokyo (JP).

(81) 指定国 (表示のない限り、全ての種類の国内保護が可能): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) 指定国 (表示のない限り、全ての種類の広域保護が可能): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), ユーラシア (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), ヨーロッパ (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

添付公開書類:

- 国際調査報告書
- 補正書

2 文字コード及び他の略語については、定期発行される各 PCT ガゼットの巻頭に掲載されている「コードと略語のガイダンスノート」を参照。

(54) Title: ANTIPSYCHOTIC MOLECULAR-TARGETING EPITHELIAL GROWTH FACTOR RECEPTOR

(54) 発明の名称: 上皮成長因子受容体を分子標的とする抗精神病薬

(57) Abstract: It is intended to provide a drug which is useful in preventing and/or treating mental diseases, integration dysfunction syndrome and cognitive dysfunction. As a means of resolution, an epithelial growth factor receptor activity inhibitor is provided as a remedy for mental diseases, integration dysfunction syndrome and cognitive dysfunction.

(57) 要約: 本発明は、精神病、統合失調症、認知機能障害の予防及び/又は治療薬に有用な薬物を提供することを目的とする。解決手段として、上皮成長因子受容体の活性阻害剤を精神病、統合失調症、認知機能障害の治療剤として提供する。



WO 2004/060400 A1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/000002

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl⁷ A61K45/00, 31/517, 31/519, 31/4709, 31/47, 31/4741,
31/496, A61P25/18, 25/28, 43/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl⁷ A61K45/00, 31/00-80, A61P25/18, 25/28, 43/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAPLUS (STN), REGISTRY (STN), MEDLINE (STN), BIOSIS (STN)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	FUTAMURA T. et al., Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients, Molecular Psychiatry, 2002, No.7, pages 673 to 682	1-16
A	Gibson K. H. et al., Epidermal growth factor receptor tyrosine kinase: structure-activity relationships and antitumour activity of novel quinazolines., Bioorganic & Medicinal Chemistry Letters, 1997, Vol.7, No.21, pages 2723 to 2728	1-16

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
26 March, 2004 (26.03.04)

Date of mailing of the international search report
13 April, 2004 (13.04.04)

Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.